Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
PHL Treatment in Pancreatic Cancer

This proposal will investigate the effect of paricalcitol, hydroxychloroquine, and losartan (PHL) combination of 3 stroma-modifying drugs on pancreatic adenocarcinoma and its stroma.

  • 0 views
  • 04 Oct, 2022
  • 1 location
Paricalcitol Improves Anemia of Inflammation (PIERAID)

Anemia of inflammation (AI) is a common comorbidity in hemodialysis patients. Paricalcitol is a selective vitamin D receptor activator with potential benefits on anti-inflammatory cytokines

vitamin d
vitamins
epoetin beta
transferrin saturation
calcium
  • 30 views
  • 04 Oct, 2022
  • 1 location
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be evaluated. The

paclitaxel
fluorouracil
capecitabine
ct scan
adenocarcinoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer

This phase II trial investigates how well paricalcitol and hydroxychloroquine work when combined with gemcitabine and nab-paclitaxel in treating patients with pancreatic cancer that has spread

metastasis
vitamin d
blood transfusion
chemotherapy drug
paclitaxel
  • 0 views
  • 05 Mar, 2021
  • 3 locations
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with

chronic kidney disease stage 5
secondary hyperparathyroidism
kidney disease
nephropathy
vitamin d
  • 8 views
  • 03 May, 2022
  • 10 locations
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

the addition of paricalcitol to nab-paclitaxel concurrently with dose-escalated radiation therapy. In addition, after the MTD of the nab-paclitaxel is reached in sub-trial 1 arm A, in the second part

  • 55 views
  • 29 Nov, 2021
  • 1 location